Thank you for subscribing!
Finfeed Archived Mar 09, 2021
Neurotech International Limited (ASX: NTI) has announced a strategic cultivation partnership with CannaPacific Limited to grow and maintain genetic stock and assist in the development of elite varietal strains through their exclusive licencing agreement.
Finfeed Archived Mar 02, 2021
Neurotech International Limited (ASX: NTI) has expanded its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, disease or affliction affecting the human brain function, specifically - Autism, Epilepsy, ADHD, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue and Migraine.
Finfeed Archived Feb 15, 2021
Following the successful in vitro findings, Neurotech (ASX: NTI) has begun designing a phase I/II study to assess the safety and efficacy of the novel NTI/Dolce strain in a paediatric population.
Finfeed Archived Dec 21, 2020
Neurotech International Ltd (ASX: NTI) has today confirmed the successful completion of in-vitro studies using human brain cells to assess and validate the anti-inflammatory and neuro-modulatory properties of its proprietary DOLCE/NTI cannabis leads.
Get expert stock analysis direct in your inbox
Finfeed Archived Apr 01, 2020
OncoSil Medical Ltd (ASX: OSL) has received CE Marking approval from the British Standards Institute (BSI) for its OncoSil™ device.
Join Our Mailing List
